Effects of Turmeric on Homocysteine and Fetuin-A in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Placebo-Controlled Study

被引:11
|
作者
Ghaffari, Aida [1 ]
Rafraf, Maryam [2 ]
Navekar, Roya [3 ]
Sepehri, Bita [4 ]
Asghari-Jafarabadi, Mohammad [5 ,6 ]
Ghavami, Seyyed-Mostafa [7 ]
Manafi, Nahid [8 ]
机构
[1] Tabriz Univ Med Sci, Fac Nutr & Food Sci, Students Res Comm, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Nutr & Food Sci, Dept Community Nutr, Tabriz, Iran
[3] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[4] Tabriz Univ Med Sci, Fac Med, Dept Gastroenterol & Hepatol, Tabriz, Iran
[5] Tabriz Univ Med Sci, Rd Traff Injury Res Ctr, Tabriz, Iran
[6] Tabriz Univ Med Sci, Fac Hlth, Dept Stat & Epidemiol, Tabriz, Iran
[7] Tabriz Univ Med Sci, Fac Paramed, Dept Radiol, Tabriz, Iran
[8] Sanjesh Lab, Tehran, Iran
关键词
Turmeric; Homocysteine; Fetuin-A; Nonalcoholic Fatty Liver; INSULIN-RESISTANCE; SERUM FETUIN; ENDOTHELIAL DYSFUNCTION; METABOLIC SYNDROME; CURCUMIN; PLASMA; RATS; ASSOCIATION; OBESITY; RISK;
D O I
10.5812/ircmj.43193
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Elevated levels of homocysteine (Hcy) and fetuin-A are important risk factors for cardiovascular diseases in patients with a nonalcoholic fatty liver disease (NAFLD). There is limited evidence regarding the effects of turmeric on NAFLD. Objectives: This study aimed at investigating the effects of turmeric supplementation on serum levels of Hcy and fetuin-A in patients with NAFLD. Methods: In this double-blind, randomized, controlled clinical trial, 46 NAFLD patients (21 males and 25 females; age range, 20-60 years) with body mass index ranged 24.9 - 40 kg/m(2) were recruited from Sheikh-ol-Raees clinic in Tabriz City, Iran during Nov 2014May 2015. The participants were allocated into the two groups using the block randomization method. The intervention and control groups received 3g of turmeric (n = 23) and placebo (n = 23), daily for 12 weeks. Fasting blood samples were collected at baseline and at the end of the trial for biochemical analysis. Results: Turmeric supplementation significantly decreased serum levels of Hcy, compared with the placebo group at the end of the study (by 27.83%, P = 0.034). No significant difference was observed between the two groups in serum levels of fetuin-A after the intervention (P > 0.05). Serum levels of glucose, insulin and homeostasis model assessment for insulin resistance were declined significantly in the turmeric group (by 1.22%, 17.69% and 19.48%, P = 0.039, P = 0.013 and P = 0.001, respectively) compared to the placebo. Conclusions: Turmeric consumption had beneficial effects on serum Hcy levels andmaybe useful inmanagementof this risk factor in NAFLD patients.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Effects of AIF on Knee Osteoarthritis Patients: Double-blind, Randomized Placebo-controlled Study
    Park, Sung-Hoon
    Kim, Scong-Kyu
    Shin, Im-Hee
    Kim, Hyung-Gun
    Choe, Jung-Yoon
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2009, 13 (01): : 33 - 37
  • [22] Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study
    Taslimi, Shervin
    Vahidi, Hamed
    Pourvaziri, Ali
    Modabbernia, Amirhossein
    Fallah, Arezoo Yeke
    Yazdani, Nasrin
    Taslimi, Negin
    Hosseini, Mostafa
    Zarandi, Masoud Motesadi
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2013, 270 (05) : 1635 - 1641
  • [23] Ondansetron in patients with tinnitus: randomized double-blind placebo-controlled study
    Shervin Taslimi
    Hamed Vahidi
    Ali Pourvaziri
    Amirhossein Modabbernia
    Arezoo Yeke Fallah
    Nasrin Yazdani
    Negin Taslimi
    Mostafa Hosseini
    Masoud Motesadi Zarandi
    European Archives of Oto-Rhino-Laryngology, 2013, 270 : 1635 - 1641
  • [24] The effects of Zataria multiflora Boiss. (Shirazi thyme) on nonalcoholic fatty liver disease and insulin resistance: A randomized double-blind placebo-controlled clinical trail
    Zamani, Nasrindokht
    Shams, Mesbah
    Nimrouzi, Majid
    Zarshenas, Mohammad Mehdi
    Foroughi, Amin Abolhasani
    Abarghooei, Ebrahim Fallahzadeh
    Fattahi, Mohammad Reza
    COMPLEMENTARY THERAPIES IN MEDICINE, 2018, 41 : 118 - 123
  • [25] Inhibition of 11β-Hydroxysteroid dehydrogenase-1 with AZD4017 in patients with nonalcoholic steatohepatitis or nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, phase II study
    Yadav, Yogesh
    Dunagan, Kelly
    Khot, Rachita
    Venkatesh, Sudhakar K.
    Port, John
    Galderisi, Alfonso
    Cobelli, Claudio
    Wegner, Craig
    Basu, Ananda
    Carter, Rickey
    Basu, Rita
    DIABETES OBESITY & METABOLISM, 2022, 24 (05): : 881 - 890
  • [26] Value of fetuin-A as a predictor of liver fibrosis in patients with nonalcoholic fatty liver disease
    Sertoglu, Erdim
    Dogru, Teoman
    Ercin, Cemal N.
    LIVER INTERNATIONAL, 2015, 35 (08) : 2061 - 2061
  • [27] Pentoxifylline for treatment of nonalcoholic fatty liver disease (NAFLD): A randomized, placebo-controlled study
    Buranawuti, W.
    Thong-u-thaisri, P.
    Pramoolsinsap, C.
    Wisedopas, N.
    Atamasirikul, K.
    Udomsubpayakul, U.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S264 - S265
  • [28] Pentoxifylline for treatment of nonalcoholic fatty liver disease (NAFLD): A randomized, placebo-controlled study
    Buranawuti, Warawuti
    Thong-u-thaisri, Panida
    Pramoolsinsap, Chutima
    Wisedopas, Naruemon
    Atamasirikul, Kalayanee
    Udomsubpayakul, Umaporn
    GASTROENTEROLOGY, 2007, 132 (04) : A330 - A330
  • [29] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
    Stephen A. Harrison
    Federico Perez Manghi
    William B. Smith
    Diana Alpenidze
    Diego Aizenberg
    Naomi Klarenbeek
    Chi-Yi Chen
    Eli Zuckerman
    Eric Ravussin
    Phunchai Charatcharoenwitthaya
    Pin-Nan Cheng
    Helena Katchman
    Samuel Klein
    Ziv Ben-Ari
    Anisha E. Mendonza
    Yiming Zhang
    Miljen Martic
    Shenglin Ma
    Sheena Kao
    Sandra Tanner
    Alok Pachori
    Michael K. Badman
    YanLing He
    Chinweike Ukomadu
    Eric Sicard
    Nature Medicine, 2022, 28 : 1432 - 1438
  • [30] Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study
    Harrison, Stephen A.
    Manghi, Federico Perez
    Smith, William B.
    Alpenidze, Diana
    Aizenberg, Diego
    Klarenbeek, Naomi
    Chen, Chi-Yi
    Zuckerman, Eli
    Ravussin, Eric
    Charatcharoenwitthaya, Phunchai
    Cheng, Pin-Nan
    Katchman, Helena
    Klein, Samuel
    Ben-Ari, Ziv
    Mendonza, Anisha E.
    Zhang, Yiming
    Martic, Miljen
    Ma, Shenglin
    Kao, Sheena
    Tanner, Sandra
    Pachori, Alok
    Badman, Michael K.
    He, YanLing
    Ukomadu, Chinweike
    Sicard, Eric
    NATURE MEDICINE, 2022, 28 (07) : 1432 - +